Available Technology

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes ofBacillus anthracisLethal Factor (LF), a critical component of theB. anthracislethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention ofB. anthracisinfection. They may also allow screening forB. anthracisLF in a sample and development of a peptide anthrax vaccine.
Patent Abstract: 
B. anthracis
Benefits 
Potentially faster, lower-input assay compared to current Edema Factor detection methods -Easily adaptable for high-throughput screening of numerous specimens
applications 
Inventors: 
Conrad Quinn
Patent Number: 
61/699,738
Internal Laboratory Ref #: 
E-210-2013/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin